Journal
EUROPEAN JOURNAL OF INTERNAL MEDICINE
Volume 23, Issue 2, Pages 126-131Publisher
ELSEVIER
DOI: 10.1016/j.ejim.2011.10.007
Keywords
DPP-4 inhibitor; GLP-1 receptor agonist; Incretin; Sitagliptin; Exenatide; Liraglutide
Categories
Funding
- AstraZeneca/BMS
- Eli Lilly
- GlaxoSmithKline
- Merck Sharp Dohme
- Novartis
- NovoNordisk
- Sanofi-Aventis
- Servier
- Takeda
Ask authors/readers for more resources
The pharmacological treatment of type 2 diabetes (T2DM) is becoming increasingly complex, especially since the availability of incretin-based therapies. Compared with other glucose-lowering strategies, these novel drugs offer some advantages such as an absence of weight gain and a negligible risk of hypoglycaemia and, possibly, better cardiovascular and beta-cell protection. The physician has now multiple choices to manage his/her patient after secondary failure of metformin, and the question whether it is preferable to add an oral dipeptidylpeptidase-4 (DPP-4) inhibitor (gliptin) or an injectable glucagon-like peptide-1 (GLP-1) receptor agonist will emerge. Obviously, DPP-4 inhibitors offer several advantages compared with GLP-1 receptor agonists, especially regarding easiness of use, tolerance profile and cost. However, because they can only increase endogenous GLP-1 concentrations to physiological (rather than pharmacological) levels, they are less potent to improve glucose control, promote weight reduction (weight neutrality) and reduce blood pressure compared to GLP-1 receptor agonists. Of note, none of the two classes have proven long-term safety and positive impact on diabetic complications yet. The role of DPP-4 inhibitors and GLP-1 receptor agonists in the therapeutic armamentarium of T2DM is rapidly evolving, but their respective potential strengths and weaknesses should be better defined in long-term head-to-head comparative controlled trials. Instead of trying to answer the question whether DPP-4 inhibitors are favourable to GLP-1 receptor agonists (or vice versa), it is probably more clinically relevant to look at which T2DM patient will benefit more from one or the other therapy considering all his/her individual clinical characteristics (personalized medicine). (C) 2011 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available